50 Presentations from Top Biopharma at PEGS Europe 2020

They Must Be Compatible: Mutual Interaction Phenomena between Protein Formulation and Siliconized/Silicone-Free Syringe Packaging Materials with an Effect on Functionality and Stability
Karoline B. Bechtold-Peters, PhD, Senior Strategy & Technology Leader, Pharmaceuticals & Biopharma Process, Novartis Pharma AG

Targeting Bispecific Biologics to Disease Tissues
Lorenzo Benatuil, PhD, Senior Principal Research Scientist & Head, Biologics, AbbVie

Exploring the Non-Ideality of High-Concentration Biopharmaceutical Formulations by AUC
Alexander Bepperling, PhD, Lab Head, Biophysical Characterisation II, Technical R&D/Technical Development Biosimilars, Novartis Global Drug Development

Mim8: Development of a Next-Generation Factor VIII-Mimetic Bispecific Antibody
Jais R. Bjelke, PhD, Senior Scientist, Global Research, Novo Nordisk AS

Development and Application of High-Throughput MAM Approach to Support Process Development of Site-Specific ADC Intermediates
Nick Bond, PhD, Senior Scientist, Analytical & CMC Team Lead, AstraZeneca

Bispecific Antibodies – Next-Generation Molecules & Applications
Ulrich Brinkmann, PhD, Expert Scientist, Pharma Research & Early Development, Roche Innovation Center Zurich

Large-Scale NBEs Continuous Manufacturing: From Concept to Reality
Johan Chami, Scientist, Drug Substance Clinical Operations, Global Healthcare Operations, Biotech Process Sciences, Merck Serono SA

Case Study of EGFR-cMET Molecule Now in Late-Stage Development
Mark L. Chiu, PhD, Associate Director, Development, Janssen Research

Determining Binding Affinities of Therapeutic Antibodies Targeting Transmembrane Proteins
Tony Christopeit, PhD, Research Scientist, Pharma Research & Early Development, Roche Diagnostics GmbH

Display-Based Approaches for Antibody Developability Optimization
Orla Cunningham, PhD, Senior Director, Biomedicine Design, Pfizer Inc.

Optimising C7 Antibodies for High Affinity and Developability
Susannah Davis, Scientific Leader, BioPharm, GlaxoSmithKline

Antibody Discovery Is More than Just Binders
Ruud M. De Wildt, PhD, Director & Biopharm R&D Head, Lead Discovery, GlaxoSmithKline

Engineering the Next Generation of Therapeutics
John Delaney, PhD, Director, Research Technologies and Collaborations, Amgen

Development and Application of Screening Assays to Predict Aggregation upon Long- Term Storage
Fabian Dingfelder, PhD, Industrial Postdoc, Biophysics, Novo Nordisk AS

Tumor-Conditional Anti-CTLA4 Uncouples Antitumor Efficacy from Immunotherapy- Related Toxicity
Feng Dong, PhD, Principal Research Scientist II, Foundational Immunology, AbbVie Cambridge Research Center

Towards ML-Enabled Antibody Drug Discovery at Bayer: Vision and Step-Wise Approach
Philipp Ellinger, Dr rer nat, Lab Head, Analytical Biochemistry, Biologics Research, Cell, Gene and Protein Sciences, Bayer AG

Challenges in Characterization and Developability Assessments of Multispecific Antibodies
Melanie Fischer, PhD, Section Head Assays and Analytics, Biologics Research, Sanofi

Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy, Aimovig (Erenumab)
Fernando Garces, PhD, Senior Scientist and Group Lead, Protein Engineering, Therapeutics Discovery, Amgen, Inc.

Manipulating Dendritic Cell (DC) Biology to Impact T Cell Functional Differentiation
Tariq Ghayur, PhD, Distinguished Research Fellow, Foundational Immunology, AbbVie

A Novel Approach in Middle-Down Biologics Characterization
Francois Griaud, PhD, Functional Lead & Principal Scientist, Analytical Development & Characterization, Novartis Pharma AG

Immune Modulation by Targeted Antigen Delivery to and Metabolic Manipulation of Antigen-Presenting Cells (APCs)
Subramanya Hegde, PhD, Principal Research Scientist II, AbbVie

Anti-BCMA in Phase III Testing
Axel X. Hoos, MD, PhD, Senior Vice President, R&D Governance Chair, and Therapeutic Area (TA) Head, Oncology, GlaxoSmithKline

From Glassware to Software: Better Understanding of Chemical Degradation Mechanisms by Physics-Based Simulations
Saeed Izadi, PhD, Scientist, Early Stage Pharmaceutical Development, Genentech, Inc.

Targeting Pro-Tumor Inflammation Via the Inflammasome Pathway
Pushpa Jayaraman, PhD, Senior Investigator I, Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research

Chemical Modifications in Biotherapeutic Proteins and Their Impact on HOS and Function
Sambit R. Kar, PhD, Principal Scientist & Head, Biophysics Center of Excellence, Bristol Myers Squibb Co.

BiTE® Antibody Constructs for the Treatment of Cancer
Roman Kischel, MD, Director, Research & Early Development Lead, Oncology, Amgen Research Munich GmbH

PD1-X: Targeting PD-1 with Bispecific Agents
Christian Klein, PhD, Cancer Immunotherapy Discovery, Roche Pharma Research & Early Development, Roche Innovation Center Zurich

Inclusion Body Processing: A REAL Black Box Case Study
Daniel Kronberger, Head, Downstream Pilot, Process Science, Boehringer Ingelheim RCV GmbH & Co. KG

The ABCs of Outsourcing ADCs: Analytical Transfers, Buy vs. Make, and Considerations for Effective CMO Management
Jens Lohrmann, PhD, Head, Oncology Disease Area, Technical R&D Development Novel Biologics Entities, Portfolio Management, Novartis Pharma AG

Rapid Discovery of Anti-Viral Antibodies and Development as Gene Therapies for Pandemic Prevention
David Lowe, PhD, Senior Director, R&D, Antibody Discovery and Protein Engineering, AstraZeneca

mAbs vs. Bugs: Antibody Therapies for Infectious Disease
Steve Martin, PhD, Vice President, Biopharm Discovery, GlaxoSmithKline

Allosteric Anti-Tryptase Antibodies for the Treatment of Mast-Cell Mediated Severe Asthma
Henry Maun, PhD, Associate Director, External Innovation, Roche

Oncolytic Virus and Antibody-Drug Conjugate-Based Therapeutic Combinations: Different Modalities – Common Themes
Philipp Mueller, PhD, Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co KG

HexElect® Technology: Therapeutic IgG Antibody Combinations Acting as Biologic AND Gates
Simone Oostindie, MSc, Scientist, Translational Research, Genmab BV

Presence of a Positive Charge Cluster on Fc-fusion of Mouse LIGHT Impacts Its Exposure and in vivo Activity in Mice
Ayse Meric Ovacik, PhD, Scientist, Developmental Sciences, Genentech, Inc.

Identification of HCPs Inducing Particle Formation during Protein Stability Testing
Veronika Reisinger, PhD, Lab Head, Physico Chemical Characterization, Novartis AG

AUC Characterization of Empty, Partial, and Full AAV Particles
Chris Rogers, Senior Scientist, Allergan Biologics

The Tumor Microenvironment Instructs Divergent Monocyte Fates that Determine Response to Anti-PDL1 Treatment
Shahram Salek-Ardakani, PhD, Senior Director, Cancer Immunology Discovery, Pfizer Inc.

Challenges of the Day-to-Day Lab-Scale Protein Production and How to Overcome Them
Peter Schmidt, PhD, Director, Recombinant Technologies, R&D, CSL Behring GmbH

Rapid Identification of Highly Potent Fully Human Anti-CCR-1 Antagonist mAbs
Martin Scott, PhD, Scientific Leader & Associate Fellow, GlaxoSmithKline

Small-Angle Neutron and X-Ray Scattering: Emerging Biophysical Tools for Frozen and Freeze-Dried Biologicals
Evgenyi Y. Shalaev, PhD, Research Investigator, Pharmaceutical Development, Allergan, Inc.

Combinatorial Approaches to Enhance Bispecific Anti-Tumor Efficacy
Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.

Predicting Solution Behavior during Developability Screening
Charles G. Starr, PhD, Scientist, Developability & Preformulation Sciences, Sanofi Group

New Factor VIII Function-Mimetic Bispecific Antibodies Engineered from Emicizumab for Further Improving the Treatment of Haemophilia A
Yuri Teranishi, Research Scientist, Discovery Research, Chugai Pharmaceutical Co., Ltd.

Use of a Targeted Integration CHO Host for Stable Cell Line Development: Insights & Applications
Mark Trautwein, Dr rer nat, Senior Scientist, Biologics Platform, Bayer AG

From Formulation Screening to Early Manufacturing
Bernhard Valldorf, PhD, Principal Scientist & Lab Head, Formulation Development, EMD Serono

In Pursuit of Quality Molecules: Early Biophysical Characterization Tools for the Prediction of in vivo Stability
Sathya Venkataramani, PhD, Associate Director, Biophysics, BDS, Janssen Biotherapeutics

Cell Line Development for Biologics R&D
Bernd Voedisch, PhD, Principal Scientist II, Novartis Pharma AG

Development of Novel Native LC-MS Methods and Solutions for the Characterization of mAbs and Related Products
Shunhai Wang, PhD, Senior Staff Scientist, Analytical Chemistry, Regeneron Pharmaceuticals Inc.

Modulating the Receptor Binding Site of Immunoligands for Enhanced Potency and Efficacy
Stefan Zielonka, PhD, Associate Director, Protein Engineering & Antibody Technologies, Merck KGaA